Close Menu
iTechArtGroup
    Facebook X (Twitter) Instagram
    Trending
    • America’s Longest Shutdown: 43 Days That Closed the Federal Government
    • The First CRISPR Medicine Rewrites the Treatment of Sickle Cell Disease
    • Panduan Lengkap Pemain Baru di situs gwp555: Mulai dengan Aman dan Menyenangkan
    • Why Does Slot Maxwin Require Patience During the Base Game Phase?
    • The Changing Role of Digital Platforms in Casino Entertainment
    • Digital Transformation and the Changing World of Casino Entertainment
    • Inside the Modern Casino Industry: Digital Innovation, Entertainment, and Changing Technology
    • Binance Plans Asia Expansion After Record Crypto Heist
    Facebook X (Twitter) Instagram YouTube
    iTechArtGroup
    • Home
    • Technology
    • Business
    • Finance
    • Health
    • Education
    • Reviews
    iTechArtGroup
    Home»Blog»The First CRISPR Medicine Rewrites the Treatment of Sickle Cell Disease
    Blog

    The First CRISPR Medicine Rewrites the Treatment of Sickle Cell Disease

    Leonor FernandesBy Leonor FernandesNovember 21, 2026No Comments3 Mins Read0 Views
    Facebook Twitter Pinterest LinkedIn Telegram Tumblr Email
    Red blood cells seen under a microscope.

    In December 2023, regulators in the United States approved the first medicine based on CRISPR gene editing, a treatment for sickle cell disease called Casgevy. Sickle cell disease is caused by a single faulty gene that makes red blood cells stiff and crescent-shaped, blocking blood vessels and causing severe pain, organ damage and early death. Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, works by taking a patient’s own blood stem cells, editing them in the laboratory to switch off a gene called BCL11A, and returning them to the patient. Switching off that gene reactivates the production of foetal haemoglobin, the form of the oxygen-carrying protein babies make before birth, which does not sickle. The US Food and Drug Administration approved it on 8 December 2023, and Britain and the European Union followed, with England’s NHS agreeing a deal for eligible patients in August 2024.

    What the Evidence Shows

    The approval is a landmark for genetic medicine, because it proves that editing a patient’s own DNA can treat a disease, not just in theory but in practice. In trials, most treated patients went at least a year without the painful crises that define sickle cell disease, and many remained free of them for far longer. But the treatment is also a test of whether such medicine can reach the people who need it. It costs about 2.2 million dollars per patient, requires months of preparation including chemotherapy to clear the bone marrow, and can only be given in specialist centres. Sickle cell disease affects millions of people, most of them in sub-Saharan Africa, where the treatment is currently out of reach. The science has arrived; the challenge now is making it affordable and available. Reporting and analysis from sources such as Nature track the same developments, and specialists following first CRISPR medicine Casgevy say the direction is now consistent across independent lines of evidence.

    The Wider Context

    The wider context is a research landscape in which replication and open data now decide reputations. Findings connected to first CRISPR medicine Casgevy are being checked by independent groups with shared datasets, and the teams involved publish their methods in full so rivals can test every step. That discipline is slower than a headline cycle, but it is why results in this area increasingly survive first contact with scrutiny.

    What Happens Next

    What happens next in the story of first CRISPR medicine Casgevy will be decided by follow-up work already under way: larger samples, longer observation and instruments that have not yet come online. The researchers involved are unusually united on one point, that the current results justify the next investment of time and money. Readers will not have to wait long for the first tests of that claim. You can follow related developments in our coverage of science.

    None of this will be settled by a single announcement, study or product launch. The pattern to watch is accumulation: independent confirmations, honest reporting of failures and steady improvement in the underlying numbers. Readers who follow those signals, rather than the loudest claim of the week, will understand this subject better than most of the commentary surrounding it suggests is possible.

    CRISPR gene therapy sickle cell disease
    Leonor Fernandes

    Related Posts

    America’s Longest Shutdown: 43 Days That Closed the Federal Government

    November 21, 2026

    Panduan Lengkap Pemain Baru di situs gwp555: Mulai dengan Aman dan Menyenangkan

    November 20, 2026

    Why Does Slot Maxwin Require Patience During the Base Game Phase?

    November 20, 2026

    The Changing Role of Digital Platforms in Casino Entertainment

    November 20, 2026

    Digital Transformation and the Changing World of Casino Entertainment

    November 19, 2026

    Inside the Modern Casino Industry: Digital Innovation, Entertainment, and Changing Technology

    November 19, 2026
    Leave A Reply Cancel Reply

    Search
    Recent Posts

    We Tested the Asus TUF Gaming T500 – Here’s What We Found

    October 4, 2025346 Views

    Choosing the Right Term Length for Maximum Returns

    April 11, 2026248 Views

    How to Translate WhatsApp Messages on Android and iPhone

    October 4, 2025216 Views

    Why Players Are Switching to LU88 in 2026

    June 16, 2026189 Views

    How Successful Candidates Approach the IBPS RRB Clerk Exam

    January 12, 2026162 Views

    Back Pain in Teenagers Due to Screen Time: Causes & Fixes

    February 27, 2026157 Views
    About Us

    iTechArtGroup delivers expert insights across technology, business, finance, health, education, reviews.

    Trusted platform sharing research, trends, analysis, tools, strategies, innovations for professionals, startups, enterprises, educators, investors. #iTechArtGroup.

    | เว็บพนันออนไลน์ | สล็อตเว็บตรง | สล็อตเว็บตรง | ufabet | สล็อต | เว็บยูฟ่า | เบทฟิก | เว็บสล็อต | WIN79 | ดูบอล | เว็บแทงบอลออนไลน์ | แทงบอล UFABET

    Popular Posts

    Oracle Database on AWS, Azure and Google Cloud: What Multi-cloud Means for a DBA

    November 17, 2026

    Cutting Back on Alcohol Brings Noticeable Health Benefits

    November 17, 2026

    Bottega Desires Outfit Ideas: Modern Streetwear and Everyday Styling Inspiration

    November 13, 2026
    Contact Us

    We appreciate your feedback! If you have a question, need assistance, or would like to connect, please don’t hesitate to reach out. Our team is always here to help you.

    Email: [email protected]
    Phone: +62 823 19299387

    Address: 757 Coffman Alley
    Elizabethtown, KY 42701

     แทงบอลออนไลน์ | แทงบอลออนไลน์ | 로얄클럽 커뮤니티 | 프라그마틱 무료슬롯

    Facebook X (Twitter) Instagram Pinterest YouTube Dribbble
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    • Terms and Conditions
    • Write For Us
    • Sitemap
    Copyright © 2026 | All Rights Reserved | iTechArtGroup

    Type above and press Enter to search. Press Esc to cancel.

    WhatsApp us